Award
NIH Reporter #1R01AI201701-01
Immunomodulatory Blockade of Type 2 Immunity for Severe Coccidioidomycosis
Recipient
University of California Los Angeles
Award Amount
$787,484.00
Ceiling
$787,484.00
Awarded
August 11, 2026
Identifier
1R01AI201701-01
A clinical trial funded by NIH/NIAID to evaluate dupilumab for severe coccidioidomycosis by modulating Type 2 immunity, led by Principal Investigator Manish Butte at UCLA.
Description
This project involves a clinical trial to evaluate the efficacy of dupilumab in treating severe coccidioidomycosis by modulating Type 2 immune responses. The project is funded by NIH/NIAID and involves collaboration across hospitals in California. The project aims to determine clinical outcomes and immunologic effects of the intervention.